OUHSC Among First to Offer New FDA-Approved Proton Therapy System

The Stephenson Cancer Center will be among the first in the world to offer proton therapy with a smaller, first-of-its-kind system newly approved by the FDA.

The MEVION S250 Proton Therapy System is unique in that it was developed to provide the same precise, non-invasive treatment advantages and capabilities of complex, large and costly proton therapy systems but with higher patient volume, improved reliability, and lower implementation and operational costs. It is scheduled for delivery to the Stephenson Cancer Center this fall.

“Being on the cutting edge of medical technology is exciting and a hallmark of top academic-based, comprehensive cancer centers. It means Oklahomans with cancer will soon have access to the absolute newest proton therapy technology at the Stephenson Cancer Center in Oklahoma City,” said Robert Mannel, MD, director of the Stephenson Cancer Center.

The MEVION S250 Proton Therapy System is designed to deliver precise and intense proton beams that physicians can use to treat cancerous tumors and lesions while sparing healthy tissue. The proton accelerator is only 6-feet in diameter, a fraction of the size of existing proton systems around the country.

The broad adoption of proton therapy has been greatly limited by the enormous cost, large footprint, and technical complexity of traditional proton therapy systems. Powered by a patented TriNiobium Core™, the MEVION S250 proton therapy system redefines the economics, availability and the future direction of proton therapy, by bringing the management and operation of proton therapy to levels similar to modern X-ray radiation therapy devices.

“This is an important milestone. It is wonderful to know that the Stephenson Cancer Center will very soon be home to this revolutionary device,” said M. Dewayne Andrews, MD, MACP, Senior Vice President and Provost of the University of Oklahoma Health Sciences Center and Executive Dean of the OU College of Medicine.

The Stephenson Cancer Center plans to open its proton therapy center early next year. The FDA gave 510(k) clearance this week for the MEVION S250 Proton Therapy System made by Mevion Medical Systems Inc.

“Proton therapy is yet another of the many tools provided by a comprehensive cancer center like ours to help bring the best care and hope to patients with cancer,” Mannel added.

The Stephenson Cancer Center is one of only 35 primary sites nationally in the Radiation Therapy Oncology Group and already conducts many trials with traditional radiation therapy. The addition of the MEVION S250 Proton Therapy System will provide new opportunities to conduct research aimed at determining how and in what cancers proton therapy can be most effective.